Jhanelle Gray | Moffitt

Dr. Jhanelle E. Gray, M.D.

Claim this profile

Moffitt Cancer Center

Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
18 reported clinical trials
30 drugs studied

About Jhanelle E. Gray, M.D.

Education:

  • Graduated with Honors, B.S., University of Florida (1993–1997).
  • Earned M.D., Cornell University Medical College (1997–2001).

Experience:

  • Completed Medicine Internship and Residency, The New York Presbyterian Hospital - Cornell (2001–2004).
  • Hematology/Medical Oncology Fellowship, Moffitt Cancer Center (2010–2011).
  • Serves as Clinical Instructor and Mentor at Moffitt Cancer Center and University of South Florida (2007–present).
  • Holds positions as Department Chair, Program Leader, and Senior Member for Thoracic Oncology at Moffitt Cancer Center.
  • Appointed Co-Leader of the Molecular Medicine Program at Moffitt Cancer Center.

Area of expertise

1Lung Cancer
Global Leader
Jhanelle E. Gray, M.D. has run 17 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global Leader
Jhanelle E. Gray, M.D. has run 11 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.
Moffitt Cancer Center
Image of trial facility.
Moffitt Cancer Center-International Plaza

Clinical Trials Jhanelle E. Gray, M.D. is currently running

Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria

More about Jhanelle E. Gray, M.D.

Clinical Trial Related5 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Jhanelle E. Gray, M.D. has experience with
  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Nivolumab
  • Ipilimumab
  • Paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jhanelle E. Gray, M.D. specialize in?
Is Jhanelle E. Gray, M.D. currently recruiting for clinical trials?
Are there any treatments that Jhanelle E. Gray, M.D. has studied deeply?
What is the best way to schedule an appointment with Jhanelle E. Gray, M.D.?
What is the office address of Jhanelle E. Gray, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security